TriangleHEALTH PROFESSIONAL · SOURCE READING
Bendamustine with rituximab
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia
Evidence (bendamustine with rituximab):
A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]
Source links and citations
A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]
The overall response rate was 100%, and the complete remission rate was 50%.[30][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice